Compare Amylx Pharmaceuticals Inc (AMLX) vs MGM Resorts International (MGM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs MGM Resorts International — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while MGM Resorts International trades at $47.79 (market cap $11.99B). The key difference: MGM Resorts International is far larger — about 6.1× Amylx Pharmaceuticals Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MGM | |
|---|---|---|
Market Cap | $1.98B | $11.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $50.69 |
52-Week Low | $7.64 | $30.72 |
Enterprise Value | $1.70B | $41.04B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
MGM Resorts International (MGM) trades at $46.88, up 0.95% on the day, with a bullish technical signal and mixed earnings history. The stock shows strong revenue growth from $13.1B in 2022 to $17.5B in 2025, though net income margins have compressed to 1.03%. Recent news highlights potential acquisition talks with Barry Diller at $48.30 per share, while analyst consensus is evenly split between Buy and Hold ratings.
Outlook: MGM offers exposure to gaming and hospitality recovery with a reasonable P/S of 0.71, but high P/E of 64.22 reflects margin pressures. Risks include earnings volatility, debt levels, and regulatory scrutiny. The Diller bid provides near-term upside potential, but execution on profitability remains key for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
